Alta Sciences

AUGUST 29, 2024

Engaging at the outset with a fully integrated and experienced drug development partner can ensure safety, with timely data sharing at every step of the drug development plan, and facilitate agile, flexible decision-making and planning. billion USD by 2028. billion USD in 2023 to $166.53 Image thumbnail-qh33.jpg

Drug Development 52

Drug Development Small Molecule Clinical Trials Drugs 52

Perficient: Drug Development

DECEMBER 29, 2023

percent by the statutory deadline of September 30, 2028. percent by September 30, 2028. percent by the statutory deadline of September 30, 2028. This action became necessary due to extraordinary deposit growth during the first half of 2020, causing the DIF’s reserve ratio to dip below 1.35

Compliance 52

Compliance 52

Alta Sciences

APRIL 5, 2024

The mini documentary explores transformation in the slow-to-change drug development industry. Leaders from Altasciences dive into the obstacles and inefficiencies of the traditional outsourcing relationship between CROs and drug sponsors, and how Altasciences has broken from tradition to address these challenges.

Drug Development 52

Drug Development Pharma Companies Marketing Drugs 52

Perficient: Drug Development

SEPTEMBER 25, 2023

According to Forrester, “Investment in hospital equipment will grow from $36 billion in 2018 to $262 billion in 2028. And that’s easy to understand due to the plethora of available options and new solutions entering the market each day. Yet, HCPs often purchase technology on a team-by-team basis.”

Nurses 98

Nurses Hospitals Production Marketing 98

Perficient: Drug Development

SEPTEMBER 19, 2023

jobs by 2028. This solidifies that Salesforce is leading the charge in AI, and Perficient is leaning into the partnership to bring innovative solutions to our clients. We learned about new Salesforce capabilities and technologies, heard new product announcements, and connected with peers and clients from across industries.

Licensing 59

Licensing Licensing Production Marketing 59

DrugBank

AUGUST 9, 2024

This high attrition rate directly results from the scientific and regulatory hurdles that drug candidates must overcome. The Investment Landscape Despite these challenges, the potential rewards for successful drug development are substantial. trillion by 2028. trillion dollars, and it is forecasted to exceed 1.4

Pharmaceuticals 76

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 76

Agency IQ

AUGUST 16, 2024

By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. The study is planned to begin in 2026 and conclude in 2028.

FDA 40

FDA Trials Therapies Regulations 40